Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Golodirsen

The articles shown below are all about the Golodirsen, through these related articles, you can get relevant information, notes in use, or latest trends about the Golodirsen. We hope these news will give you the help you need. And if these Golodirsen articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 09 2024

    2024-12-09

    This week, there are 9 drugs in the patent and exclusivity list. They are: - SANDOZ INC's HYCAMTIN, containing active ingredient TOPOTECAN HYDROCHLORIDE - MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZEPATIER, containing active ingredient ELBASVIR; GRAZOPREVIR - NOVARTIS PHARMACEUTICALS CORP's KISQALI FEMARA CO-PACK (COPACKAGED), containing active ingredient LETROZOLE; RIBOCICLIB SUCCINATE - NOVARTIS PHARMACEUTICALS CORP's KISQALI, containing active ingredient RIBOCICLIB SUCCINATE - SAREPTA THERAPEUTICS INC's VYONDYS 53, containing active ingredient GOLODIRSEN - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB - PFIZER INC's XELJANZ XR, containing active ingredient TOFACITINIB CITRATE - PF PRISM CV's XELJANZ, containing active ingredient TOFACITINIB CITRATE - CALLIDITAS THERAPEUTICS AB's TARPEYO, containing active ingredient BUDESONIDE Read More